Comparison of high‐power short‐duration and low‐power long‐duration radiofrequency ablation for treating atrial fibrillation: Systematic review and meta‐analysis
Background High power shorter duration (HPSD) ablation seen to increase efficacy and safety treating of atrial fibrillation (AF); however, comparative data between HPSD and low power longer duration (LPLD) ablation are limited. Hypothesis We thought that HPSD might bring more clinical benefits. The...
Saved in:
Published in | Clinical cardiology (Mahwah, N.J.) Vol. 43; no. 12; pp. 1631 - 1640 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Wiley Periodicals, Inc
01.12.2020
John Wiley & Sons, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
High power shorter duration (HPSD) ablation seen to increase efficacy and safety treating of atrial fibrillation (AF); however, comparative data between HPSD and low power longer duration (LPLD) ablation are limited.
Hypothesis
We thought that HPSD might bring more clinical benefits. The aim of this meta‐analysis was to evaluate the clinical benefits of HPSD in patients with AF.
Methods
The Medline, PubMed, Embase, and the Cochrane Library databases were searched for studies comparing HPSD and LPLD ablation.
Results
Ten trials with 2467 patients were included in the analysis. Pooled analyses demonstrated that HPSD showed a benefit of first‐pass pulmonary vein isolation (PVI) (risk ratio [RR]: 1.20; 95% confidence interval [CI]: 1.10‐1.31, P < .001) and recurrence of atrial arrhythmias (RR: 0.73; 95% CI: 0.58‐0.91, P = .005). Additionally, HPSD could reduce procedural time (weighted mean difference [WMD]: −42.93; 95% CI, −58.10 to −27.75, P < .001), ablation time (WMD: −21.01; 95% CI: −24.55 to −17.47, P < .001), and fluoroscopy time (WMD: −4.11; 95% CI: −6.78 to −1.45, P < .001). Moreover, major complications and esophageal thermal injury (ETI) were similar between two groups (RR: 0.75; 95% CI: 0.44‐1.30, P = .31) and (RR: 0.57; 95% CI: 0.21‐1.51, P = .26).
Conclusions
HPSD was safe and efficient for treating AF. Compared with LPLD, HPSD was associated with advantages of procedural features, higher first‐pass PVI and reducing recurrence of atrial arrhythmias. Moreover, major complications and ETI were similar between two groups. |
---|---|
Bibliography: | Funding information Hangzhou Health Science and Technology Project, Grant/Award Number: 2016A02 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Chao‐feng Chen and Jing Wu contributed equally to this study. Funding information Hangzhou Health Science and Technology Project, Grant/Award Number: 2016A02 |
ISSN: | 0160-9289 1932-8737 |
DOI: | 10.1002/clc.23493 |